Escalon® Announces Launch of Escalon Clinical Diagnostics™

WAYNE, Pa., May 16, 2011 -- Escalon Medical Corp. (Nasdaq: ESMC) today announced the integration of Drew Scientific and JAS Diagnostics brands to form Escalon Clinical Diagnostics™. Previously independent subsidiaries and brands of Escalon Medical Corp., the two companies have now come together to offer a wide and growing product range while continuing to provide the highest level of innovation, reliability, and customer support for which both Drew Scientific and JAS Diagnostics have been known.

“We are excited to offer both of the Drew and JAS products under the single brand of Escalon Clinical Diagnostics, which reflects our integration of operations and leverages all resources of the company,” commented Richard J. DePiano, Chairman and Chief Executive Officer. “We ultimately believe our customers will recognize the value-added a single company can provide in terms of product offering, customer service, and technical support.”

The introduction of the Escalon Clinical Diagnostics™ brand will occur over the next several months and will be featured at the upcoming 2011 AACC Annual Meeting in Atlanta, GA July 24-28. It should be noted that no change in legal entity names will occur at this time.

Founded in 1987, the Company (www.escalonmed.com) develops, markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Company’s distribution capabilities, although such partnerships or acquisitions may not occur. The Company has headquarters in Wayne, Pennsylvania and operations in Long Island, New York, New Berlin, Wisconsin, Stoneham, Massachusetts, Dallas, Texas, Waterbury, Connecticut, Miami Lakes, Florida, Barrow-in-Furness, U.K. and Le Rheu, France.

Forward-Looking Statements

Certain of the statements contained herein may be, within the meaning of the federal securities laws, “forward-looking statements,” which are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements -- which uncertainties or risks includes the Company’s ability to generate sufficient cash from operations or future financings of which there can be no assurance. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. See the Company’s Form 10-K for the fiscal year ended June 30, 2010 for a discussion of such risks, uncertainties and other factors. These forward-looking statements are based on management’s expectations as of the date hereof, and the Company does not undertake any responsibility to update any of these statements in the future.